A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

The Chaim Sheba Medical Center /ID# 254884, Ramat Gan, Tel Aviv, Israel

Hadassah Medical Center-Hebrew University /ID# 254885, Jerusalem, Israel

University of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona, United States

Sylvester Comprehensive Cancer Center - University of Miami /ID# 247232, Miami, Florida, United States

Allina Health System /ID# 251782, Minneapolis, Minnesota, United States

University of Nebraska Medical Center /ID# 246715, Omaha, Nebraska, United States

Memorial Sloan Kettering Cancer Center-Koch Center /ID# 249246, New York, New York, United States

Novant Health Presbyterian Medical Center /ID# 246719, Charlotte, North Carolina, United States

Baylor Sammons Cancer Center /ID# 247715, Dallas, Texas, United States

University of Texas Health San Antonio MD Anderson Cancer Center /ID# 256234, San Antonio, Texas, United States

Concord Repatriation General Hospital /ID# 249240, Concord, New South Wales, Australia

St Vincent's Hospital Melbourne /ID# 247624, Fitzroy Melbourne, Victoria, Australia

One Clinical Research Pty Ltd /ID# 248392, Nedlands, Western Australia, Australia

Cross Cancer Institute /ID# 246717, Edmonton, Alberta, Canada

University Health Network_Princess Margaret Cancer Centre /ID# 243936, Toronto, Ontario, Canada

Seoul National University Hospital /ID# 263945, Seoul, Seoul Teugbyeolsi, South Korea

Asan Medical Center /ID# 263220, Seoul, Seoul Teugbyeolsi, South Korea

Samsung Medical Center /ID# 263294, Seoul, Seoul Teugbyeolsi, South Korea

Hospital Universitario Marques de Valdecilla /ID# 262826, Santander, Cantabria, Spain

Hospital Universitario Fundacion Jimenez Diaz /ID# 265198, Madrid, Spain